A private California biotechnology company has signed a two-year option agreement with Case Western Reserve University and Dartmouth College to advance a novel immunotherapy to treat cancer and infectious diseases.
Mosaic ImmunoEngineering Inc. of Novato, Calif., was granted the exclusive right to license the technology for a novel platform that uses virus-like nanoparticles (VLP) to treat and prevent cancer and infectious diseases in humans and for veterinary use, according to a news release.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published September 4, 2020.